Latest Breaking News On - Dabur honitus - Page 9 : comparemela.com
News18 Lokmat welcomes Lord Ganesha with special show Bappa Morya Re
adgully.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from adgully.com Daily Mail and Mail on Sunday newspapers.
Dabur expands Hajmola portfolio with new LimCola flavour
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Dabur India shares hit fresh record high on robust growth outlook
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
How Dabur is upping its ayurvedic game
Thinking ahead: Mohit Malhotra
Recipe for success: Dabur also plans to invest ₹550 crore to ramp up its existing manufacturing capacity
Booster shot: Dabur Chyawanprash is one of the company’s ₹1,000 crore power brands
1/3
2/3
Recipe for success: Dabur also plans to invest ₹550 crore to ramp up its existing manufacturing capacity
3/3
×
The 137-year-old company is capitalising on its herbal heritage and banking on nine power brands to grow during the pandemic
The ongoing Covid-19 pandemic has ushered in change. If it brought some business to a standstill, it also led to the grand transformation of several FMCG behemoths from slow process-oriented elephants into nimble panthers. Especially remarkable is the case of Dabur India. The 137-year-old company demonstrated a feline-like speed and ferocity in pouncing on new opportunities, overhauling its go-to-market strategy and capitalising on its ayurvedic lineage.
The FMCG major reported 34.4% jump in consolidated net profit to Rs 377.8 crore on 25.3% rise in revenue from operations to Rs 2,336.8 crore in Q4 FY21 over Q4 FY20.
Material cost increased by 26.1% to Rs 1,197.9 crore in Q4 FY21 from Rs 949.6 crore in Q4 FY20. EBITDA was at Rs 527.4 crore in Q4 FY21, up by 23.2% from Rs 428.1 crore in Q4 FY20. EBITDA margin was at 22.6% as on 31 March 2021 as compared to 22.9% as on 31 March 2020.
The company s healthcare piece reported a strong 23% growth in Q4 with the Ayurvedic Ethicals business growing by 39.1%, OTC business reporting a growth of 34%, the Digestives business growing by 20%, and the Health Supplements category ending the quarter with a nearly 18% growth.